cagrisema novo nordisk

Novo Nordisk's next-gen obesity drug Cagrisema

Novo Nordisk defends next-gen obesity drug CagriSema, details new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.

Fortune · 1d

Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

devdiscourse · 2h

Novo Nordisk's Bold Bet: CagriSema's Next Chapter in Obesity Treatment

Novo Nordisk defends its obesity drug CagriSema despite disappointing late-stage trial data that significantly affected its market value. The company plans a new trial in 2025 due to positive weight-loss indicators,

Hosted on MSN · 34m

Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from legally selling cheap knockoff versions.

Reuters on MSN · 7h

Novo Nordisk's new CagriSema study to focus on dose escalation and trial length

Novo Nordisk on Wednesday said its new trial of its next-generation obesity drug candidate CagriSema will look at dose escalation and trial length to further show the drug's potential, after data in December disappointed the market.

Novo Nordisk Stock Rises

Reuters · 2h

Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.

Benzinga.com · 5h

Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in 2025, with results expected in Q1.

Investopedia on MSN · 5h

Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid "intensifying competition.

16m

Novo Nordisk A/S Is Being Sued For Securities Law Violations And The Schall Law Firm Urges Investors With Losses To Reach Out

LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Novo Nordisk beats on Wegovy sales, expects slower 2025 growth

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

NVO CLASS ACTION: BFA Law Alerts Novo Nordisk Investors of the Imminent March 25 Class Action Deadline

New York, New York-- (Newsfile Corp. - February 5, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

10h

Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Financial report for the period 1 January 2024 to 31 December 2024 Operating profit increased by 25% in Danish kroner and by ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results